American Journal of Cardiology
Volume 105, Issue 3 , Pages 297-301 , 1 February 2010

Safety and In-Hospital Outcomes of Bivalirudin Use in Dialysis Patients Undergoing Percutaneous Coronary Intervention

Received 24 August 2009 ,Revised 16 September 2009 ,Accepted 16 September 2009.

References 

  1. Blackman DJ, Pinto R, Ross JR, Seidelin PH, Ing D, Jackevicius C, et al. Impact of renal insufficiency on outcome after contemporary percutaneous coronary intervention. Am Heart J. 2006;151:146–152
  2. Osten MD, Ivanov J, Eichhofer J, Seidelin PH, Ross JR, Barolet A, et al. Impact of renal insufficiency on angiographic, procedural, and in-hospital outcomes following percutaneous coronary intervention. Am J Cardiol. 2008;101:780–785
  3. Lemos PA, Arampatzis CA, Hoye A, Daemen J, Ong AT, Saia F, et al. Impact of baseline renal function on mortality after percutaneous coronary intervention with sirolimus-eluting stents or bare metal stents. Am J Cardiol. 2005;95:167–172
  4. Bonello L, De Labriolle A, Roy P, Steinberg DH, Okabe T, Pinto Slottow TL, et al. Impact of optimal medical therapy and revascularization on outcome of patients with chronic kidney disease and on dialysis who presented with acute coronary syndrome. Am J Cardiol. 2008;102:535–540
  5. Best PJ, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol. 2002;39:1113–1139
  6. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853–863
  7. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355:2203–2216
  8. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218–2230
  9. Kastrati A, Neumann FJ, Mehilli J, Byrne RA, Iijima R, Buttner HJ, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med. 2008;359:688–696
  10. Lincoff AM, Bittl JA, Kleiman NS, Sarembock IJ, Jackman JD, Mehta S, et al. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol. 2004;93:1092–1096
  11. Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med. 1995;333:764–769
  12. Chew DP, Bhatt DL, Kimball W, Henry TD, Berger P, McCullough PA, et al. Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. Am J Cardiol. 2003;92:919–923
  13. Chew DP, Lincoff AM, Gurm H, Wolski K, Cohen DJ, Henry T, et al. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). Am J Cardiol. 2005;95:581–585
  14. ANGIOMAX prescribing information. Parsippany, NJ: The Medicines Company; December 6, 2005;www.angiomax.comAccessed August 24, 2009
  15. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, et al Thrombolysis in Myocardial Infarction (TIMI) Trial, phase i: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase (Clinical findings through hospital discharge). Circulation. 1987;76:142–154
  16. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41
  17. Robson R. The use of bivalirudin in patients with renal impairment. J Invasive Cardiol. 2000;12(Suppl F):33F–36F
  18. Robson R, White H, Aylward P, Frampton C. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender. Clin Pharmacol Ther. 2002;71:433–439
  19. Reed MD, Bell D. Clinical pharmacology of bivalirudin. Pharmacotherapy. 2002;22:105S–111S

PII: S0002-9149(09)02401-1

doi: 10.1016/j.amjcard.2009.09.030

American Journal of Cardiology
Volume 105, Issue 3 , Pages 297-301 , 1 February 2010

Article Tools